Oculis (NASDAQ:OCS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Oculis (NASDAQ:OCS) in a research report sent to investors on Monday,Benzinga reports. They currently have a $30.00 price target on the stock.

Oculis Trading Up 0.5 %

NASDAQ:OCS opened at $17.65 on Monday. The firm has a fifty day simple moving average of $16.33 and a two-hundred day simple moving average of $13.79. Oculis has a 12 month low of $10.50 and a 12 month high of $18.10. The stock has a market capitalization of $714.90 million, a price-to-earnings ratio of -9.15 and a beta of -0.33. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.